MILAN & DARMSTADT, Germany--(BUSINESS WIRE)--ESMO Abstract Numbers: 274O, 882P, 596P, 1031P, 1033P Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux® (cetuximab) in a range of solid tumor types – including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.
